Tectonic Therapeutic is a clinical-stage biotech building biologic medicines that modulate G protein-coupled receptors (GPCRs), a major but hard-to-drug target class. Its proprietary GEODe platform aims to discover therapeutic proteins and antibodies that conventional approaches have struggled to produce. Lead candidate TX45 is an engineered Fc-relaxin fusion protein designed to activate the RXFP1 receptor, with additional programs aimed at serious conditions such as hereditary hemorrhagic telangiectasia. The company targets diseases with limited treatment options where GPCR biology is central.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -20 | — |
| Q3 2025 | 0 | — | -19 | — |
| Q4 2025 | 0 | — | -19.2 | — |
| Q1 2026 | 0 | — | -25.2 | — |
| Q2 2026 | 0 | — | -22.3 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: AVITA Medical, Inc. (RCEL), Falcon's Beyond Global, Inc. (FBYD), New Providence Acquisition Corp. III (NPAC), Osprey Acquisition Corp. III (OSPR), SEALSQ Corp (LAES), AlTi Global, Inc. (ALTI)